ALEXION PHARMACEUTICALS INC.

In News

Alexion Securities Class Action Lawsuit - Settlement - Motley Rice

Motley Rice - Nov 05, 2025

Alexion Pharmaceuticals discloses C1S inhibitors - bioworld.com

bioworld.com - Jan 16, 2026

Novartis Says Alexion's 'Block The Cause' Ads Are False - Law360

Law360 - Oct 21, 2025

ANTITRUST—D. Mass.: ‘Pay for delay’ claims against Alexion survive on sham litigation exception to Noerr-Pennington - VitalLaw.com

VitalLaw.com - Jan 05, 2026

AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial - BioPharma Dive

BioPharma Dive - Jul 24, 2025

Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (g - Yahoo Finance

Yahoo Finance - Aug 07, 2025

JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines - BioSpace

BioSpace - Jul 08, 2025

AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters

Reuters - Apr 17, 2025

AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News

Bloomberg Law News - Apr 17, 2025

JCR’s third deal with Alexion gives rights to AAV capsids - bioworld.com

bioworld.com - Jul 15, 2025

Alexion Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

ACCESS Newswire - Apr 25, 2025

Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies - AstraZeneca

AstraZeneca - Jul 28, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment